NCT04222920View on ClinicalTrials.gov

Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity

PHASE4CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

September 11, 2023

Study Completion Date

September 11, 2023

Conditions
Rheumatoid Arthritis
Interventions
OTHER

Dose reduction to 2mg/L

Adalimumab dose reduction aiming drug concentration of 2mg/L

OTHER

Dose reduction to 5mg/L

Adalimumab dose reduction aiming drug concentration of 5mg/L

DRUG

Adalimumab

Adalimumab

Trial Locations (1)

1056AB

Reade Rheumatology Research Institute, Amsterdam

All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Sint Maartenskliniek

OTHER

lead

Reade Rheumatology Research Institute

OTHER

NCT04222920 - Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity | Biotech Hunter | Biotech Hunter